Pharmacosmos

IV iron therapeutics

Privately held: no public share price · Denmark

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Ferric derisomaltose(Monoferric / Monofer)
Approved
Iron repletionOther
Heart FailureChronic Kidney DiseaseIron Deficiency Anemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Ferric derisomaltose · Monoferric / MonoferPhase 3Iron Deficiency, Anaemia in Children
Est. primary completion 2027-04-30 · NCT05179226 · CT.gov ↗
What to watch
December 2027 (1)
Ferric derisomaltose · Monoferric / MonoferPhase 3Chronic Heart Failure, Iron Deficiencies
Est. primary completion 2027-12-01 · NCT06929806 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.